» Articles » PMID: 32220902

Mortality in Biopsy-proven Alcohol-related Liver Disease: a Population-based Nationwide Cohort Study of 3453 Patients

Overview
Journal Gut
Specialty Gastroenterology
Date 2020 Mar 30
PMID 32220902
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Patients with alcohol-related liver disease (ALD) are at increased risk of death, but studies have rarely investigated the significance of histological severity or estimated relative risks compared with a general population. We examined mortality in a nationwide cohort of biopsy-proven ALD.

Design: Population-based cohort study in Sweden comparing 3453 individuals with an International Classification of Disease (ICD) code for ALD and a liver biopsy from 1969 to 2017 with 16 535 matched general population individuals. Swedish national registers were used to ascertain overall and disease-specific mortality, starting follow-up at the latest of first ICD diagnosis or liver biopsy plus 3 months. Cox regression adjusted for relevant confounders was used to estimate HRs in ALD and histopathological subgroups.

Results: Median age at diagnosis was 58 years, 65% were men and 52% had cirrhosis at baseline. Five-year cumulative mortality was 40.9% in patients with ALD compared with 5.8% in reference individuals. The risk for overall mortality was significantly increased (adjusted HR (aHR)=4.70, 95% CI 4.35 to 5.08). The risk of liver-related death was particularly high (43% of all deaths, aHR=167.6, 95% CI 101.7 to 276.3). Mortality was significantly increased also in patients with ALD without cirrhosis and was highest in the first year after baseline but persisted after ≥10 years of follow-up (aHR=2.74, 95% CI 2.37 to 3.16).

Conclusion: Individuals with biopsy-proven ALD have a near fivefold increased risk of death compared with the general population. Individuals with ALD without cirrhosis were also at increased risk of death, reaffirming the need to increase vigilance in the management of these individuals.

Citing Articles

MetALD: Clinical aspects, pathophysiology and treatment.

Gratacos-Gines J, Arino S, Sancho-Bru P, Bataller R, Pose E JHEP Rep. 2025; 7(2):101250.

PMID: 39897615 PMC: 11782861. DOI: 10.1016/j.jhepr.2024.101250.


BC99 Attenuates Oxidative Stress Induced by Acute Alcoholic Liver Injury via Nrf2/SKN-1 Pathway and Liver Metabolism Regulation.

Wu Y, Li C, Gao Y, Zhang J, Dong Y, Zhao L Antioxidants (Basel). 2025; 14(1.

PMID: 39857451 PMC: 11760874. DOI: 10.3390/antiox14010117.


The steatotic liver disease burden paradox: unravelling the key role of alcohol.

Torp N, Israelsen M, Krag A Nat Rev Gastroenterol Hepatol. 2024; .

PMID: 39639157 DOI: 10.1038/s41575-024-01022-y.


Dual peroxisome proliferator-activated receptor α/δ agonists: Hope for the treatment of alcohol-associated liver disease?.

Zhang X, Chen Q, Zhu F, Li M, Shang D World J Gastroenterol. 2024; 30(37):4163-4167.

PMID: 39474402 PMC: 11514538. DOI: 10.3748/wjg.v30.i37.4163.


Impact of alcohol use on liver disease outcomes.

Desalegn H, Diaz L, Rehm J, Arab J Clin Liver Dis (Hoboken). 2024; 23(1):e0192.

PMID: 38860129 PMC: 11164003. DOI: 10.1097/CLD.0000000000000192.